Key Outcomes: XellSmart (XS411, Parkinson’s): P1 (n=9) showed >30-point average improvement in OFF-state MDS-UPDRS Part III and >5 hr/day of added ON time without troublesome dyskinesia at 6 months. There were no DLTs, SAEs, tumors, or graft-induced dyskinesia. Enrollment is complete for the 30-patient P2 in China. Muna (MNA-001, Alzheimer’s): P1 showed favorable safety, strong […]

Key Outcomes: Survodutide (Boehringer Ingelheim) – P3 SYNCHRONIZE-2, obesity and T2D: Met both co-primary endpoints at Wk 76; achieved up to 13.1% weight loss and 1.21 percentage-point HbA1c reduction vs pbo. GI-related discontinuations were higher (18% vs 1.2%) Rina-S (Genmab) – P1/2 RAINFOL-01, platinum-resistant ovarian cancer: Demonstrated a 45.9% cORR, 12.1 mos mDoR and 9.5 […]

Key Outcomes: R-5780 (Rise Therapeutics) – P1, immuno-oncology: Dose-escalation complete; IDMC approved advancing to dose-expansion at the highest selected fixed dose in up to 33 cancer patients with PD-1-refractory tumors IMVT-1402 (Immunovant/Roivant) – P2 PoC, CLE: Missed primary endpoint (CLASI-A at wk 12 vs pbo, n=56); development in CLE discontinued. No impact on ongoing programs […]

Key Outcomes: Novartis remibrutinib (P3 REMODEL-1/2, RMS) – Met primary endpoint; superior ARR reduction vs teriflunomide, positive secondary/MRI endpoints, clean liver safety Clover RSV+hMPV±PIV3 vaccines (P2, older adults) – Strong neutralizing antibody responses across all targets; no immune interference; ~62% fewer reported RTIs vs pbo Novo Nordisk semaglutide (P3 STEP Young, pediatric obesity) – Met […]